Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $6.9 million.

  • Enanta Pharmaceuticals' Receivables - Net rose 355.1% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 355.1%. This contributed to the annual value of $6.9 million for FY2025, which is 355.1% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Receivables - Net of $6.9 million as of Q3 2025, which was up 355.1% from $8.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Receivables - Net's 5-year high stood at $27.6 million during Q4 2021, with a 5-year trough of $6.6 million in Q3 2024.
  • In the last 5 years, Enanta Pharmaceuticals' Receivables - Net had a median value of $17.8 million in 2023 and averaged $14.7 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first surged by 1592.77% in 2021, then plummeted by 6381.23% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Receivables - Net (Quarter) stood at $27.6 million in 2021, then decreased by 18.31% to $22.6 million in 2022, then plummeted by 63.81% to $8.2 million in 2023, then fell by 5.57% to $7.7 million in 2024, then fell by 10.83% to $6.9 million in 2025.
  • Its Receivables - Net was $6.9 million in Q3 2025, compared to $8.3 million in Q2 2025 and $6.8 million in Q1 2025.